Yaara Ofir-Rosenfeld

Yaara Ofir-Rosenfeld has been working in the field of oncology since 2009. Yaara began their career as a Postdoctoral Fellow at the Weizmann Institute of Science, followed by a Postdoctoral Fellow at the University of Cambridge in 2009. At the University of Cambridge, they were a Post-doctoral researcher at Ashok Venkitaraman's group in the Hutchsion/MRC Cancer Cell Unit, focusing on BRCA2 and DNA damage signalling. In 2013, they joined MISSION Therapeutics as a Senior Scientist. In 2018, they joined STORM Therapeutics Limited, where they have held the roles of Director of Translational Oncology, Principal Scientist of Target and Biomarker Validation, and Senior Scientist of Target and Biomarker Validation.

Yaara Ofir-Rosenfeld obtained a Bachelor of Science (BSc) in Biochemistry and Molecular Biology from the Technion - Israel Institute of Technology in 1998-2001. Yaara then continued their studies at the same institution, earning a Master of Science (MSc) in Cell/Cellular and Molecular Biology, Cell Cycle, and yeast genetics in 2001-2003. Finally, Yaara Ofir-Rosenfeld achieved a Doctor of Philosophy (PhD) in Oncology and Cancer Biology from the Weizmann Institute of Science in 2003-2008.